KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Total Debt (2017 - 2025)

Novartis Ag (NVS) has disclosed Total Debt for 9 consecutive years, with $28.7 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 30.54% to $28.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 billion through Dec 2025, up 30.54% year-over-year, with the annual reading at $28.7 billion for FY2025, 30.54% up from the prior year.
  • Total Debt hit $28.7 billion in Q4 2025 for Novartis Ag, up from $22.0 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $29.2 billion in Q4 2021 to a low of $19.1 billion in Q4 2023.
  • Historically, Total Debt has averaged $25.0 billion across 5 years, with a median of $26.2 billion in 2022.
  • Biggest five-year swings in Total Debt: fell 27.18% in 2023 and later surged 30.54% in 2025.
  • Year by year, Total Debt stood at $29.2 billion in 2021, then dropped by 10.35% to $26.2 billion in 2022, then dropped by 27.18% to $19.1 billion in 2023, then grew by 15.47% to $22.0 billion in 2024, then soared by 30.54% to $28.7 billion in 2025.
  • Business Quant data shows Total Debt for NVS at $28.7 billion in Q4 2025, $22.0 billion in Q4 2024, and $19.1 billion in Q4 2023.